CN102159226A - 增加剖宫产出生婴儿的IgA分泌的益生菌 - Google Patents
增加剖宫产出生婴儿的IgA分泌的益生菌 Download PDFInfo
- Publication number
- CN102159226A CN102159226A CN2009801365363A CN200980136536A CN102159226A CN 102159226 A CN102159226 A CN 102159226A CN 2009801365363 A CN2009801365363 A CN 2009801365363A CN 200980136536 A CN200980136536 A CN 200980136536A CN 102159226 A CN102159226 A CN 102159226A
- Authority
- CN
- China
- Prior art keywords
- baby
- application
- probiotic bacteria
- nutrient compositions
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 44
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 44
- 230000028327 secretion Effects 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 230000000529 probiotic effect Effects 0.000 claims abstract description 38
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 45
- 229920001542 oligosaccharide Polymers 0.000 claims description 27
- 150000002482 oligosaccharides Chemical class 0.000 claims description 27
- 235000015097 nutrients Nutrition 0.000 claims description 18
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 11
- 230000000813 microbial effect Effects 0.000 description 10
- 235000013406 prebiotics Nutrition 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 208000034423 Delivery Diseases 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000009677 vaginal delivery Effects 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- 102000002268 Hexosaminidases Human genes 0.000 description 3
- 108010000540 Hexosaminidases Proteins 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N 3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229940060155 neuac Drugs 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- IXWNIYCPCRHGAE-DFZOHVKFSA-N alpha-D-GalNAc-(1->3)-D-Gal Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O IXWNIYCPCRHGAE-DFZOHVKFSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000538 anti-polioviral effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ORYOIBJWFDNIPD-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O ORYOIBJWFDNIPD-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 150000008272 galactosaminides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
益生菌在制造药物或治疗性营养组合物中的应用,该药物或治疗性营养组合物用于使剖宫产分娩的婴儿在婴儿生命的最初四个月期间增加IgA分泌。
Description
发明领域
本发明涉及将益生菌给予剖宫产分娩的婴儿,以增加其生命最初四至六个月期间的IgA分泌。
发明背景
婴儿出生前的胃肠道被认为是无菌的。在正常的出生过程中,婴儿的胃肠道遭遇来自母亲的消化道、皮肤和环境的细菌,并且这些细菌开始建群。健康、阴道分娩、母乳喂养的2-4周大婴儿的粪便菌群可看作为此年龄段最优化的菌群,其中双歧杆菌属物种占优势地位,还有一些乳杆菌属物种和更少量诸如脆弱拟杆菌(Bacteriodes fragilis)的拟杆菌属物种,而没有诸如梭状芽孢杆菌属(Clostridia)等潜在病原菌。在大约两岁完全断奶以后,开始建立类似成年人模式的肠道菌群模式。
应注意的是,在健康、阴道分娩、母乳喂养的婴儿中,双歧杆菌属物种形成菌群的基础,占婴儿肠道中全部细菌的60-90%。母乳喂养也促进了肠道屏障的发育,与占优势地位的双歧杆菌属物种一起增强了所摄取营养的吸收并因此增强其利用。
等人已经研究了剖宫产出生的健康婴儿的粪便菌群,并将其与阴道分娩出生的婴儿对照组进行比较。他们得出结论:剖宫产分娩出生的婴儿的肠道菌群可能在出生后被扰乱高达六个月。他们特别注意到在剖宫产组中双歧杆菌属物种和乳杆菌属物种的建群率分别只在一个月和十天后达至阴道分娩组的建群率(等人,“Fecal Microflora in Heathy Infants Born by Different Methods of Delivery:Permanent Changes in Intestinal Flora After Cesarean Delivery”,Journal of Pediatric Gastroenterology and Nutrition,28:19-25)。
其他研究者提出了这种延迟/异常建群可能在婴儿的后续发育方面具有特殊的后果,并调查了这些后果与肠道菌群差异之间可能的联系。例如,Martino等人调查了6个月大时涉及在接受益生菌嗜酸乳杆菌(Lactobacillus acidophilus)菌株LAVRI-A1或安慰剂的组中,早期暴露、全身免疫发育以及早期变应性后果的建群模式和粘膜IgA产生(Martino等人,“Relationship between early intestinal colonisation,mucosal immunoglobulin A production and systemic immune development”Clinical and Experimental Allergy,38,69-78)。
对所有的婴儿都建议使用母乳。但是,在某些情况下,母乳喂养由于医学原因而不足或不成功,或者母亲选择不进行母乳喂养。针对这些情形开发了婴儿制剂。
最近,已发现人们如果摄取某些菌株的话,这些菌株会呈现有价值的性质,这已引起了相当的重视。具体来说,已发现乳杆菌属和双歧杆菌属的特定菌株能够在肠道建群,降低病原菌粘附肠上皮的能力,具有免疫调节效应并且协助维持健康状态。有时将这样的细菌称为益生菌,并且已经提出将适宜的益生菌加入到婴儿制剂中。
已经进行了广泛的研究来鉴定新型益生菌株。例如,EP 0199535、EP 0768375、WO 97/00078、EP 0577903和WO 00/53200公开了乳杆菌属和双歧杆菌属的特定菌株及其有益效果。
例如,Vancikova等人报道了用益生菌菌株E.coli O83早期人工粘膜建群刺激粘膜免疫系统除了产生特异性抗体外,还产生非特异性的分泌IgA(Vancikova等人,“The early postnatal development of salivary antibody and immunoglobulin response in children orally colonised with a non-pathogenic,probiotic strain of E.coli”Folia Microbiol(Praha)2003;48:281-7)。
Fukushima等人研究了益生菌乳双歧杆菌(Bifidobacterium lactis)株在年龄较大儿童组(15至31月大)中对IgA分泌的影响并且发现了总IgA和抗-脊髓灰质炎病毒IgA的水平增加。
在某些国家中剖宫产出生的比例持续增加,达到全部出生儿的70%。因此,很明显需要提供降低剖宫产出生的婴儿承受因为他们的出生方式造成的负面健康后果的风险的手段。在对选择剖宫产的孕妇常规给予预防剂量的抗生素的现行实践下,这种需要尤其急切。
发明概述
因此本发明提供益生菌在制造药物或治疗性营养组合物中的应用,该药物或治疗性营养组合物用于增加剖宫产分娩的婴儿在婴儿生命最初四个月期间的IgA分泌。
本发明扩展至益生菌在制造药物或治疗性营养组合物中的应用,该药物或治疗性营养组合物用于改善剖宫产分娩的婴儿在婴儿生命的最初四个月期间的粘膜免疫防御。
本发明进一步扩展至使剖宫产分娩的婴儿在婴儿生命的最初四个月期间的IgA分泌增加的方法,该方法包括向剖宫产出生且有需要的婴儿提供治疗量的益生菌。
在又一方面,本发明提供改善剖宫产分娩的婴儿在婴儿生命的最初四个月期间的粘膜免疫防御的方法,该方法包括向剖宫产出生且有需要的婴儿提供治疗量的益生菌。
不希望被理论所限制,发明人相信向剖宫产分娩的婴儿给予益生菌以某种还未完全理解的方式有益于促进那些双歧杆菌属物种在婴儿胃肠道中后续建群,这些双歧杆菌一般可见于健康的、阴道分娩的、母乳喂养的婴儿的肠道,并且这种有益建群使总IgA分泌(即,特异和非特异IgA分泌)增加至与该参照群体中天然发现的那些相当的水平。增加的IgA分泌的一个效果是增强婴儿的粘膜免疫防御。
应当注意的是促进所给予的益生菌种的建群既不是这种治疗的目的也不是这种治疗的效果,而是要促进其他物种的建群,以得到与在健康的、母乳喂养的、阴道分娩的婴儿中发现的相当的早期双歧杆菌基因型的(bifidogenic)肠道菌群。
发明具体说明
在本说明书中,下列术语具有下列含义:
“婴儿”是指12个月以下的儿童。
“益生元(prebiotic)”是指一种不可消化的食品成分,其通过选择性刺激一种或有限数量的细菌在结肠中的生长和/或活性来对宿主产生有益影响,从而改善宿主健康(Gibson和Roberfroid“Dietary Modulation of the Human Colonic Microbiota:Introducing the Concept of Prebiotics”J.Nutr 125:1401-1412)。
“益生菌”是指对宿主的健康或良好状态有有益效果的微生物细胞制剂或微生物细胞组分。(Salminen S,Ouwehand A.Benno Y.等人“Probiotics:how should they be defined”Trends Food Sci Technol.1999:10107-10)。
如无特殊说明,所有提及的百分数都是重量百分数。
益生菌可以是具有确定的益生菌特征的任何乳酸菌或双歧杆菌,其还能够促进早期双歧杆菌基因型的肠道菌群的形成。适宜的益生乳酸菌包括鼠李糖乳杆菌(Lactobacillus rhamnosus)ATCC 53103(尤其可得自芬兰的Valio Oy,商标LGG)、鼠李糖乳杆菌CGMCC 1.3724、可得自Biogaia的罗伊乳杆菌(Lactobacillus reuteri)ATCC 55730和罗伊乳杆菌DSM17938、发酵乳杆菌(Lactobacillus fermentum)VRI 003和副干酪乳杆菌(Lactobacillus paracasei)CNCM I-2116。
适宜的益生菌双歧杆菌株包括长双歧杆菌(Bifidobacterium longum)ATCC BAA-999(可购自日本Morinaga Milk Industry Co.Ltd.,商标为BB536)、Danisco出售的商标为Bb-03的短双歧杆菌(Bifidobacterium breve)菌株、Morinaga出售的商标为M-16V的短双歧杆菌和Institur Rosell(Lallemand)出售的商标为R0070的短双歧杆菌。尤其优选的双歧杆菌株是乳双歧杆菌CNCM I-3446(可获自丹麦Christian Hansen公司,商标为Bb12)。也可以使用适宜的益生菌乳酸菌和双歧杆菌的混合物。
益生菌的适宜日剂量是10e3-10e11个菌落形成单位(cfu),更优选10e7-10e10cfu。
优选益生菌与益生元共给予。适宜的益生元包括某些寡糖,例如果糖寡糖(FOS)和半乳糖寡糖(GOS)。可以使用益生元的组合,例如90%GOS与10%短链果糖寡糖(例如以商标P95出售的产品)或10%菊粉(例如以商标HP、ST或HSI出售的产品)。
尤其优选的益生元是半乳糖寡糖、N-乙酰化寡糖和唾液酸化寡糖的混合物,其中N-乙酰化寡糖包括了该寡糖混合物的0.5至4.0%,半乳糖寡糖包括了该寡糖混合物的92.0至98.5%并且唾液酸化寡糖包括了该寡糖混合物的1.0至4.0%。这一混合物在下文中被称作“优选的益生元混合物”。
适宜的N-乙酰化寡糖包括GalNAcα1,3Galβ1,4Glc和Galβ1,6GalNAcα1,3Galβ1,4Glc。N-乙酰化寡糖可通过氨基葡糖苷酶(glucosaminidase)和/或氨基半乳糖苷酶(galactosaminidase)对N-乙酰-葡萄糖和/或N-乙酰半乳糖的作用来制备。同样,N-乙酰-半乳糖转移酶和/或N-乙酰糖基转移酶也可用于此目的。N-乙酰化寡糖也可用采用各自的酶(重组或天然的)的发酵技术和/或微生物发酵来生产。后者情况下,微生物可以或者表达它们的天然酶和底物或可工程化以生产各个底物和酶。可采用单独的微生物培养或混合培养。N-乙酰化寡糖的形成可以由其从DP=1向前开始的任何聚合度(DP)开始的受体底物起始。另一个选项是己酮糖(例如果糖)的化学转化为N-乙酰己糖胺或包含寡糖的N-乙酰己糖胺,己酮糖可以是游离的或者结合到寡糖(例如乳酮糖)上,如Wrodnigg,T.M.;Stutz,A.E.(1999)Angew.Chem.Int.Ed.38:827-828所述。
适宜的半乳糖寡糖包括Galβ1,6Gal,Galβ1,6Galβ1,4GlcGalβ1,6Galβ1,6Glc,Galβ1,3Galβ1,3Glc,Galβ1,3Galβ1,4Glc,Galβ1,6Galβ1,6Galβ1,4Glc,Galβ1,6Galβ1,3Galβ1,4GlcGalβ1,3Galβ1,6Galβ1,4Glc,Galβ1,3Galβ1,3Galβ1,4Glc,Galβ1,4Galβ1,4Glc和Galβ1,4Galβ1,4Galβ1,4Glc。合成的半乳糖寡糖如Galβ1,6Galβ1,4Glc Galβ1,6Galβ1,6Glc,Galβ1,3Galβ1,4Glc,和Galβ1,6Galβ1,6Galβ1,4Glc,Galβ1,6Galβ1,3Galβ1,4Glc、Galβ1,3Galβ1,6Galβ1,4Glc,Galβ1,4Galβ1,4Glc和Galβ1,4Galβ1,4Galβ1,4Glc以及其混合物是可以以商标和商购的。寡糖的其他供应商是Dextra Laboratories、Sigma-AldrichChemie GmbH和Kyowa Hakko Kogyo Co.,Ltd。或者,可使用特异的糖基转移酶,如半乳糖基转移酶来生产中性寡糖。
适宜的唾液酸化寡糖包括NeuAcα2,3Galβ1,4Glc和NeuAcα2,6Galβ1,4Glc。这些唾液酸化寡糖可通过色谱或过滤技术从诸如动物乳液的天然来源而分离。或者,它们也可通过使用特异唾液酸转移酶的生物技术通过酶基发酵技术(重组的或天然酶)或通过微生物发酵技术来生产。后者情况下,微生物可以或者表达它们的天然酶和底物或可工程化以生产各个底物和酶。可采用单独的微生物培养或混合培养。唾液酸化寡糖的形成可以由其从DP=1向前开始的任何聚合度(DP)开始的受体底物起始。
优选对刚出生婴儿立即给予上述益生菌,并在之后至少在婴儿生命的前两个月至四个月给予。
益生菌可以直接给予婴儿,或者如果母乳喂养的话,就通过母亲给予。如果益生菌通过母亲给予,那么可以以例如片剂、胶囊、锭剂、口香糖或液体的形式作为补给物提供给母亲。优选这些补给物还包含0.2-10g/天的量的上述寡糖混合物。这些补给物可以进一步包含保护性水胶体(例如胶质、蛋白质、改性淀粉等)、粘结剂、成膜剂、成胶囊剂/材料、壁/壳材料、基质化合物、包衣、乳化剂、表面活性剂、增溶剂(油、脂肪、蜡、卵磷脂等)、吸收剂、载体、填料、共化合物、分散剂、润湿剂、加工助剂(溶剂)、流动剂、味道掩蔽剂、加重剂、胶凝剂、凝胶形成剂、抗氧化剂和抗菌剂。这些补给物也可以包含常规的药物添加剂和佐剂、赋形剂和稀释剂,包括但不限于,水、任何来源的明胶、植物胶、磺酸木质素、滑石、糖、淀粉、阿拉伯胶、植物油、聚亚烷基二醇、调味剂、防腐剂、稳定剂、乳化剂、缓冲剂、润滑剂、色素、润湿剂、填料等。在所有情况下,这些进一步的组分可以根据它们对想要的受体的适合性来选择。
或者,可以将这些益生菌以治疗性营养组合物的形式给予母亲。该组合物可以是全营养制剂。
根据本发明用来给予泌乳妇女的全营养制剂可包括蛋白质源。可使用任何适宜的膳食蛋白质,例如动物蛋白质(例如乳蛋白、肉蛋白和卵蛋白等);植物蛋白质(例如大豆蛋白质、小麦蛋白质、稻蛋白质和豌豆蛋白质);游离氨基酸的混合物;或其组合。特别优选乳蛋白例如酪蛋白和乳清,以及大豆蛋白。该组合物也可以包含碳水化合物源和脂肪源。
如果该制剂包括除了DHA之外的脂肪源,该脂肪源优选提供该制剂5%-40%的能量;例如20%-30%的能量。可用菜籽油、玉米油和高油酸葵花籽油的共混物得到适宜的脂肪组成。
可以将碳水化合物源加入到该制剂中。其优选提供40-80%的制剂能量。可以使用任何适宜的碳水化合物,例如蔗糖、乳糖、葡萄糖、果糖、玉米糖浆固体、麦芽糖糊精及其混合物。如果需要也可加入膳食纤维。膳食纤维未经酶消化通过小肠,作为天然填充剂和通便剂发挥功能。膳食纤维可以是可溶的或不可溶的,一般优选两种类型的共混物。适宜的膳食纤维的来源包括大豆、豌豆、燕麦、果胶、瓜尔胶、阿拉伯胶。优选地,如果纤维存在,纤维含量为2-40g/l消耗的制剂,更优选4-10g/l。此外,优选该制剂还包含基于干物质重量计,2.5至15.0%,优选3.0至12.0%,更优选4.0至7.0%的量的优选的益生元混合物。
根据如USRDA等政府部门团体的建议,制剂还可包含矿物质和微量营养素,例如微量元素和维生素。例如,该制剂可包含每日剂量的一种或多种下列微量营养素:300-500mg钙、50-100mg镁、150-250mg磷、5-20mg铁、1-7mg锌、0.1-0.3mg铜、50-200μg碘、5-15μg硒、1000-3000μg β胡萝卜素、10-80mg维生素C、1-2mg维生素B1、0.5-1.5mg维生素B6、0.5-2mg维生素B2、5-18mg尼克酸、0.5-2.0μg维生素B12、100-800μg叶酸、30-70μg生物素、1-5μg维生素D、3-10IU维生素E。
如果需要的话,可加入一种或多种食品级乳化剂;例如甘油单酯和甘油二酯的二乙酰酒石酸酯、卵磷脂和甘油单酯和甘油二酯。同样也可包括适宜的盐和稳定剂。
优选该制剂是可肠内给药的;例如以可用奶或水再冲调的粉末形式。或者,或在婴儿没有母乳喂养的情况下,该益生菌可作为营养补给物给予,例如以溶于水中10e10cfu的每日剂量并用勺子给予。
对于没有母乳喂养的婴儿,该益生菌可替代地在婴儿制剂中适宜给予。
根据本发明所使用的婴儿制剂可包含不超过2.0g/100kcal,优选1.8-2.0g/100kcal的量的蛋白质源。相信蛋白质类型对于本发明并不关键,只要满足基本氨基酸的最小需求量并且能够保证满意的生长即可,但是,优选其中超过50%蛋白质源重量的是乳清。所以,可以使用基于乳清、酪蛋白及其混合物的蛋白质源,和基于大豆的蛋白质源。就乳清蛋白质来说,蛋白质源可以基于酸乳清或甜乳清或其混合物,而且可包括以任何所需比例存在的α-乳清蛋白和β-乳球蛋白。
蛋白质可以是完整的或经水解的或者完整的和经水解的蛋白质的混合物。优选提供部分水解的蛋白质(水解度2-20%),例如对于相信有发生牛奶过敏风险的婴儿。如果需要经水解的蛋白质,可以根据需要和根据本领域已知进行水解过程。例如,乳清蛋白质水解物可以通过在一个或多个步骤中酶水解乳清组分来制备。如果用作起始材料的乳清组分基本不含乳糖,发现蛋白质在水解过程中会遇到非常少的赖氨酸阻断(lysine blockage)。这使得赖氨酸阻断的程度从总赖氨酸重量的大约15%降低至少于赖氨酸重量的大约10%;例如赖氨酸重量的大约7%,这大大提高了蛋白质源的营养质量。
该婴儿制剂可包含碳水化合物源。可以使用任何常规用于婴儿制剂中的碳水化合物源,例如乳糖、蔗糖、麦芽糖糊精、淀粉及其混合物,但是优选使用乳糖作为碳水化合物源。优选该碳水化合物源贡献该制剂总能量的35-65%。
该婴儿制剂可包含脂源。脂源可以是适用于婴儿制剂的任何脂或脂肪。优选脂肪源包括棕榈油酸甘油酯、高油酸葵花籽油和高油酸红花油。如可以加入包含大量形成的花生四烯酸和二十二碳六烯酸的小量油类,例如鱼油或微生物油,基本脂肪酸亚油酸和α-亚麻酸也可以加入。总的来说,优选脂肪含量贡献该制剂总能量的30-55%。优选脂肪源中n-6脂肪酸与n-3脂肪酸的比例为大约5∶1至大约15∶1,例如大约8∶1至大约10∶1。
该婴儿制剂也可以以营养显著量包含认为对于日常膳食必须的所有维生素和矿物质。已经确定了对某些维生素和矿物质的最低需求。任选地存在于婴儿制剂中的矿物质、维生素和其他营养物质的例子包括维生素A、维生素B1、维生素B2、维生素B6、维生素B 12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、尼克酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、锰、氯、钾、钠、硒、铬、钼、牛磺酸、和L-肉碱。矿物质通常以盐的形式加入。特定矿物质和其他维生素的存在和量将根据所针对的婴儿群改变。
如果必要,该婴儿制剂可包含乳化剂和稳定剂,例如大豆卵磷脂、甘油单酯和甘油二酯的柠檬酸酯等等。
此外,该婴儿制剂也优选包含基于干物质重量计为2.5至15.0%,优选3.0至12.0%,更优选4.0至7.0%的量的该优选的益生元混合物。
该婴儿制剂可任选地包含可具有有益效果的其他物质,例如乳铁蛋白、核苷酸、核苷等。
上述的婴儿制剂和营养制剂都可以以任何适宜的方式制备。例如,可以通过将蛋白质、碳水化合物源和脂肪源以合适比例共混来制备。此时,如果使用,可以包括乳化剂。此时,可以加入维生素和矿物质,但是通常后加入,以避免热降解。任何亲脂维生素、乳化剂等可在共混前溶解入脂肪源中。然后,将水,优选经过反渗透的水混合进入,以形成液体混合物。水温适宜为大约50℃至大约80℃,以协助上述成分的分散。可用可商购的液化剂形成液体混合物。然后将该液体混合物均质化;例如以两阶段均质化。
然后可热处理液体混合物以减少细菌的携带,例如通过快速加热液体混合物至大约80℃至大约150℃范围的温度大约5秒至大约5分钟。这可通过蒸汽注入、高压灭菌或通过热交换器进行,例如平板热交换器。
然后,可以将液体混合物冷却至大约60℃至大约85℃;例如通过闪蒸冷却。然后再次将液体混合物均质化;例如在两个阶段中均质化,第一阶段大约10MPa-大约30MPa,第二阶段大约2MPa至大约10MPa。然后均质化的混合物可以进一步冷却,以加入任何热敏感的组分,例如维生素和矿物质。此时可以适宜调节均质化混合物的pH值和固体含量。
将均质化的混合物转移至适宜的干燥装置中,例如喷雾干燥器或冻干机中,变成粉末。这些粉末应该具有少于约5%重量计的水分含量。
所选择的益生菌可按照任何适宜方法培养,并通过例如冻干或喷雾干燥制备以加入到营养制剂或婴儿制剂中。备选地,细菌制剂可以从专业供应商(例如Christian Hansen和Valio)那里购买已经制备成适宜加入到诸如营养制剂和婴儿制剂等食品中的形式的成品。益生菌可以10e3-10e12cfu/g粉末的量加入到制剂中,更优选10e7-10e12cfu/g粉末。
现在参考下列实施例进一步说明本发明。
实施例1
下面给出要用于本发明的适宜婴儿制剂组合物的例子。
实施例2:
目的:开展临床试验来评估标准制剂和包含或不合益生菌长双歧杆菌(BL999,ATCC BAA-999;Morinaga,Japan)的对通过剖宫产或通过阴道分娩出生的婴儿的免疫发育的影响。
方法:3组随机双盲对照试验:
-喂以标准制剂组(酪蛋白占主要,高磷酸盐和蛋白质,低乳糖);
-喂以组(Infant Formula,商购自NestléSwitzerland,30/70的酪蛋白/乳清比,低蛋白质(1.8g/100Kcal);低磷酸盐(31mg/100Kcal)和高乳糖水平(11.1g/100Kcal);
也分析了参照母乳喂养组。
剖宫产出生的健康独生足月婴儿接受研究制剂4个月。
使用常规方法在2个月测量粪便IgA水平(μg/mL)。
在两个月的平均绝对IgA(μg/mL):
分娩模式 | 标准制剂 | NAN | NAN+BL999 | 母乳喂养 |
阴道分娩 | 25.31 | 37.24 | 39.61 | 56.06 |
剖宫产 | 19.37 | 23.11 | 33.23 | 54.20 |
结论:这些数据显示了通过剖宫产出生的婴儿具有更低的IgA产生并且富含如BL999的益生菌的婴儿制剂比标准制剂增强通过剖宫产出生的婴儿的免疫功能。它们的IgA值趋于更接近母乳喂养的IgA值。
Claims (13)
1.益生菌在制造药物或治疗性营养组合物中的应用,该药物或治疗性营养组合物用于使剖宫产分娩的婴儿在婴儿生命的最初四个月期间增加IgA分泌。
2.益生菌在制造药物或治疗性营养组合物中的应用,该药物或治疗性营养组合物用于使剖宫产分娩的婴儿在婴儿生命的最初四个月期间改善粘膜免疫防御。
3.权利要求1或2的应用,其中所述益生菌为乳酸菌。
4.权利要求3的应用,其中所述乳酸菌为鼠李糖乳杆菌ATCC 53103、鼠李糖乳杆菌CGMCC 1.3724、罗伊乳杆菌ATCC 55730、罗伊乳杆菌DSM17938、发酵乳杆菌VRI 003或副干酪乳杆菌CNCM I-2116。
5.权利要求1或2的应用,其中所述益生菌为双歧杆菌属物种。
6.权利要求5的应用,其中所述双歧杆菌属物种为乳双歧杆菌CNCMI-3446、长双歧杆菌ATCC BAA-999、短双歧杆菌Bb-03、短双歧杆菌M-16V或短双歧杆菌R0070。
7.前述任一项权利要求的应用,其中所述药物或治疗性营养组合物还包含半乳糖寡糖、N-乙酰化寡糖和唾液酸化寡糖的混合物,其中N-乙酰化寡糖占该寡糖混合物的0.5至4.0%,半乳糖寡糖占该寡糖混合物的92.0至98.5%并且唾液酸化寡糖占该寡糖混合物的1.0至4.0%。
8.前述任一项权利要求的应用,其中将所述药物或治疗性营养组合物在婴儿分娩后立即给予并在之后继续给予至少2个月。
9.前述任一项权利要求的应用,其中将所述药物或治疗性营养组合物给予婴儿的时间为分娩后至少4个月。
10.前述权利要求中任一项的应用,其中所述益生菌通过哺乳的母亲给予婴儿。
11.权利要求1-9中任一项的应用,其中所述治疗性营养组合物为婴儿制剂。
12.前述权利要求中任一项的应用,其中所述药物包含每日剂量为10e3-10e11cfu的益生菌。
13.权利要求11中任一项的应用,其中所述治疗性营养组合物包含每克干重组合物10e3-10e12cfu的益生菌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08160806A EP2147678A1 (en) | 2008-07-21 | 2008-07-21 | Probiotics to increase IgA secretion in infants born by caesarean section |
EP08160806.9 | 2008-07-21 | ||
PCT/EP2009/059072 WO2010010021A1 (en) | 2008-07-21 | 2009-07-15 | Probiotics to increase iga secretion in infants born by caesarean section |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102159226A true CN102159226A (zh) | 2011-08-17 |
CN102159226B CN102159226B (zh) | 2014-02-26 |
Family
ID=39769543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980136536.3A Active CN102159226B (zh) | 2008-07-21 | 2009-07-15 | 增加剖宫产出生婴儿的IgA分泌的益生菌 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9060540B2 (zh) |
EP (2) | EP2147678A1 (zh) |
CN (1) | CN102159226B (zh) |
AU (1) | AU2009273331B2 (zh) |
BR (1) | BRPI0916275A2 (zh) |
CA (1) | CA2731541A1 (zh) |
CL (1) | CL2011000146A1 (zh) |
ES (1) | ES2442344T3 (zh) |
MX (1) | MX2011000737A (zh) |
MY (1) | MY159072A (zh) |
PL (1) | PL2315595T3 (zh) |
PT (1) | PT2315595E (zh) |
RU (1) | RU2496505C2 (zh) |
WO (1) | WO2010010021A1 (zh) |
ZA (1) | ZA201101336B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104206539A (zh) * | 2014-08-14 | 2014-12-17 | 澳优乳业(中国)有限公司 | 一种益生菌婴幼儿奶粉 |
CN106794207A (zh) * | 2014-10-29 | 2017-05-31 | 雀巢产品技术援助有限公司 | 使用罗伊氏乳杆菌在生命早期恢复微生物群生态失调 |
CN106879253A (zh) * | 2014-05-20 | 2017-06-20 | 拜奥加亚公司 | 新生儿微生物组补充 |
CN107920579A (zh) * | 2015-08-04 | 2018-04-17 | 雀巢产品技术援助有限公司 | 用于诱导与母乳喂养的婴幼儿的肠道微生物群接近的肠道微生物群的包含动物双歧杆菌乳酸亚种(Bifidobacterium animalis ssp.lactis)以及任选的低聚糖的混合物的营养组合物和婴儿配方食品 |
CN108697141A (zh) * | 2015-12-29 | 2018-10-23 | N·V·努特里奇亚 | 含有不可消化寡糖和非复制型产乳酸细菌的营养配方物 |
CN108882740A (zh) * | 2015-12-29 | 2018-11-23 | N·V·努特里奇亚 | 含有不可消化寡糖的发酵配方物 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012009315A2 (en) * | 2010-07-12 | 2012-01-19 | The Regents Of The University Of California | Bovine milk oligosaccharides |
EP3366143A1 (en) | 2011-06-20 | 2018-08-29 | H.J. Heinz Company Brands LLC | Probiotic compositions and methods |
EP2609814A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of cognitive function |
EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
EP2811845B1 (en) * | 2012-02-10 | 2015-12-09 | N.V. Nutricia | Maternal supplement to enhance immune system of an infant |
DK2994150T3 (da) | 2013-05-10 | 2019-06-11 | Heinz Co Brands H J Llc | Probiotika og fremgangsmåde til anvendelse |
CN105899089A (zh) * | 2013-12-19 | 2016-08-24 | 雀巢产品技术援助有限公司 | 用于减少婴儿代谢应激、降低肠道通透性和接近母乳喂养婴儿的生长速度的营养组合物 |
US9980950B2 (en) | 2014-01-10 | 2018-05-29 | Nestec S.A. | Maternal vitamin B6 administration for the prevention of increased adiposity, overweight or obesity in the offspring |
US10517891B2 (en) | 2014-01-10 | 2019-12-31 | Societe Des Produits Nestle S.A. | Maternal vitamin B12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers |
RU2016141131A (ru) * | 2014-03-21 | 2018-04-23 | Нестек С.А. | Введение витамина b2 матери для профилактики повышенной тучности, избыточного веса или ожирения у потомства |
WO2016183535A1 (en) * | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
MX2019000881A (es) | 2016-07-28 | 2019-07-01 | Fonterra Cooperative Group Ltd | Producto lacteo y proceso. |
EP3618843A1 (en) * | 2017-05-05 | 2020-03-11 | Société des Produits Nestlé S.A. | Treatment of infant colic |
EP3812452A4 (en) * | 2018-09-30 | 2021-11-03 | Inner Mongolia Yili Industrial Group Co., Ltd. | BIFIDOBACTERIUM LACTIS BL-99 AND ITS USES |
CN114540247B (zh) * | 2022-03-17 | 2023-11-28 | 江南大学 | 一株可提高肠道IgA水平并缓解肠炎的发酵乳杆菌CCFM1226及其应用 |
CN114517171B (zh) * | 2022-03-17 | 2023-11-28 | 江南大学 | 一株可促进肠道分泌IgA的发酵乳杆菌CCFM1225及其应用 |
CN114540245B (zh) * | 2022-03-17 | 2023-11-28 | 江南大学 | 一株同时具有缓解抑郁情绪及促进肠道分泌IgA功能的鼠李糖乳杆菌CCFM1228及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
EP0577904B1 (fr) | 1992-07-06 | 1997-05-14 | Societe Des Produits Nestle S.A. | Bactérie lactique |
ATE161181T1 (de) | 1992-07-06 | 1998-01-15 | Nestle Sa | Lactobacillus acidophilus enthaltende antigastritis-mittel |
FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
AU2002951270A0 (en) * | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
PL1638414T3 (pl) * | 2003-06-23 | 2009-12-31 | Nestec Sa | Mleko modyfikowane niemowlęce lub następne |
JP5001830B2 (ja) * | 2005-02-02 | 2012-08-15 | 株式会社明治 | 免疫賦活用組成物 |
BRPI0608782A2 (pt) * | 2005-04-13 | 2010-01-26 | Nestec Sa | fórmula para bebê com probióticos |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
BRPI0708689A2 (pt) | 2006-03-07 | 2011-06-07 | Nestec Sa | mistura simbiótica |
EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
-
2008
- 2008-07-21 EP EP08160806A patent/EP2147678A1/en not_active Withdrawn
-
2009
- 2009-07-15 US US13/055,067 patent/US9060540B2/en active Active
- 2009-07-15 MX MX2011000737A patent/MX2011000737A/es active IP Right Grant
- 2009-07-15 ES ES09800034.2T patent/ES2442344T3/es active Active
- 2009-07-15 BR BRPI0916275A patent/BRPI0916275A2/pt not_active IP Right Cessation
- 2009-07-15 WO PCT/EP2009/059072 patent/WO2010010021A1/en active Application Filing
- 2009-07-15 CN CN200980136536.3A patent/CN102159226B/zh active Active
- 2009-07-15 EP EP09800034.2A patent/EP2315595B1/en not_active Revoked
- 2009-07-15 AU AU2009273331A patent/AU2009273331B2/en active Active
- 2009-07-15 PL PL09800034T patent/PL2315595T3/pl unknown
- 2009-07-15 MY MYPI2011000214A patent/MY159072A/en unknown
- 2009-07-15 PT PT98000342T patent/PT2315595E/pt unknown
- 2009-07-15 RU RU2011106319/15A patent/RU2496505C2/ru active
- 2009-07-15 CA CA2731541A patent/CA2731541A1/en not_active Abandoned
-
2011
- 2011-01-21 CL CL2011000146A patent/CL2011000146A1/es unknown
- 2011-02-18 ZA ZA2011/01336A patent/ZA201101336B/en unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106879253A (zh) * | 2014-05-20 | 2017-06-20 | 拜奥加亚公司 | 新生儿微生物组补充 |
CN104206539A (zh) * | 2014-08-14 | 2014-12-17 | 澳优乳业(中国)有限公司 | 一种益生菌婴幼儿奶粉 |
CN106794207A (zh) * | 2014-10-29 | 2017-05-31 | 雀巢产品技术援助有限公司 | 使用罗伊氏乳杆菌在生命早期恢复微生物群生态失调 |
CN107920579A (zh) * | 2015-08-04 | 2018-04-17 | 雀巢产品技术援助有限公司 | 用于诱导与母乳喂养的婴幼儿的肠道微生物群接近的肠道微生物群的包含动物双歧杆菌乳酸亚种(Bifidobacterium animalis ssp.lactis)以及任选的低聚糖的混合物的营养组合物和婴儿配方食品 |
CN108697141A (zh) * | 2015-12-29 | 2018-10-23 | N·V·努特里奇亚 | 含有不可消化寡糖和非复制型产乳酸细菌的营养配方物 |
CN108882740A (zh) * | 2015-12-29 | 2018-11-23 | N·V·努特里奇亚 | 含有不可消化寡糖的发酵配方物 |
Also Published As
Publication number | Publication date |
---|---|
CA2731541A1 (en) | 2010-01-28 |
MY159072A (en) | 2016-12-15 |
EP2147678A1 (en) | 2010-01-27 |
EP2315595B1 (en) | 2013-11-06 |
RU2011106319A (ru) | 2012-08-27 |
AU2009273331A1 (en) | 2010-01-28 |
EP2315595A1 (en) | 2011-05-04 |
MX2011000737A (es) | 2011-02-24 |
PT2315595E (pt) | 2013-11-25 |
CL2011000146A1 (es) | 2011-06-17 |
US9060540B2 (en) | 2015-06-23 |
CN102159226B (zh) | 2014-02-26 |
US20110129452A1 (en) | 2011-06-02 |
BRPI0916275A2 (pt) | 2015-11-10 |
ZA201101336B (en) | 2012-07-25 |
RU2496505C2 (ru) | 2013-10-27 |
AU2009273331B2 (en) | 2014-12-04 |
ES2442344T3 (es) | 2014-02-11 |
WO2010010021A1 (en) | 2010-01-28 |
PL2315595T3 (pl) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102159226B (zh) | 增加剖宫产出生婴儿的IgA分泌的益生菌 | |
CN101652079A (zh) | 减少剖腹产出生的婴儿中过敏症发生的益生菌 | |
CN102065872A (zh) | 改善肠微生物群的益生菌 | |
CN101641109A (zh) | 腹泻风险的降低 | |
EP3082828A1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section | |
CN101909636A (zh) | 包含n-乙酰基乳糖胺的寡糖用于使新生儿免疫应答成熟的应用 | |
CN107404925A (zh) | 用于预防或治疗婴儿或幼儿胃肠感染/炎症的组合物 | |
EP2127661A1 (en) | Probiotics to improve gut microbiotica | |
CN107846957A (zh) | 用于改善婴儿或幼儿粪便稠度或频率的组合物 | |
AU2018272764A1 (en) | HMOs blends for use in infants or young children for health purposes | |
CN111479573B (zh) | 用于促进肠道肌肉生长和发育以及相关联的肠道能动性的组合物 | |
CN116981463A (zh) | 人乳低聚糖 | |
CN116583187A (zh) | 用于促进幼儿中加速的丁酸盐生产的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190731 Address after: Vevey Patentee after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Patentee before: Nestle Products Technical Assistance Co., Ltd. |